Recombinant human IL-15
-
Cat.code:
rcyc-hil15
- Documents
ABOUT
Human IL-15 protein - Mammalian cell-expressed, tag-free, carrier-free
Recombinant human IL-15 is a high-quality and biologically active cytokine, validated using proprietary IL-15 reporter cells. This immunomodulating cytokine of the γc superfamily is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.
Recombinant human IL-15 can be used together with HEK-Blue™ IL-2/IL-15 cells, a cell line that detects human IL-15, for the screening of inhibitory molecules, such as Ordesekimab, a therapeutic monoclonal antibody targeting the IL-15 cytokine (see figures).
Key features
- Each lot is validated using HEK-Blue™ IL-2/IL-15 cells
- Endotoxin < 0.01 EU/µg
- 0.22 µm sterile-filtered
Applications
- T cell and NK cell activation and propagation
- IL-15 detection and quantification assays (positive control)
- Screening and release assays for antibodies blocking IL-15 signaling
- Screening and release assays for engineered IL-15 proteins
Interleukin 15 (IL-15) is an immunomodulating cytokine that is structurally and functionally related to IL-2. IL-15 promotes the ontogeny, activation, and survival of NK cells, NKT cells, T cells, and B cells. IL-15 also plays controversial roles in the development and progression of various hematological malignancies. Recombinant IL-15 can be used in combination with other cytokines like IL-2 or IL-7 to increase the efficiency of T and NK cell expansion and maturation in cell culture protocols.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
Meet the MiniKines™: Collectible Cytokine Cards
SPECIFICATIONS
Specifications
P40933
>107 IU/mg*
100 μg/ml in water
Phosphate buffer saline (pH 7.4), 5% saccharose
0.22 µm filtration
The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.
Cellular assays (tested), Cell culture (T cell and NK cell activation and expansion), ELISA
Each lot is functionally tested and validated.
*Please refer to the corresponding Certificate of Analysis (CoA) for the exact value.
CONTENTS
Contents
-
Product:Recombinant human IL-15
-
Cat code:rcyc-hil15
-
Quantity:10 µg
1.5 ml endotoxin-free water
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Interleukin 15 Signaling
IL-15 and IL-2 are two closely related cytokines that belong to the IL-2 family and display important functions in the immune system [1]. They share the heterodimeric CD122 (IL-2Rβ)/CD132 (IL-2Rγ) receptor to deliver their signals within target cells. Their specificity of action is conferred by their α receptor chains, CD25 (IL-2Rα) and CD215 (IL-15Rα). The binding of IL-15 and IL-2 to their heterodimeric or heterotrimeric receptors activates a signaling cascade through tyrosine kinases of the Janus family (JAK1 and JAK3) and signal transducer and transcription activator 5 (STAT5) [1]. This results in the subsequent induction of proliferation and anti-apoptotic transcriptional program and can, if uncontrolled, potentially lead to malignant transformation [2]. IL-15 can sustain chronic inflammation, autoimmunity, and uncontrolled T cell proliferation, leading to T cell lymphoma development [1].
IL-15 therapeutic targeting
The multi-faceted nature of IL-15, its anti-tumorigenic abilities as a booster of the immune response, and its pathogenic function as a driver of malignant cell proliferation harbors a high potential as a therapeutic tool [1]. Numerous IL-15-enhancing approaches have been used to treat different cancers, including leukemias and lymphomas, exploiting the main function of the cytokine to potentiate NK and T cell responses and unleash immune-mediated cancer eradication. On the other hand, agents that inhibit IL-15 are also being extensively tested as therapeutic approaches against cancer, such as soluble IL-15Rα, antibodies against IL-15 or components of the heterotrimeric receptor, and steric antagonists of the receptor in the form of a modified IL-2 [1]. Moreover, the IL-15 cytokine, together with IL-2 and IL-7, is currently under investigation for application in ex vivo T cell expansion. These cytokines are used in different concentrations and combinations to improve cell viability, proliferation, and differentiation in CAR T cell culture [2-3].
References:
1. Sindaco P, et al., 2023. The role of interleukin-15 in the development and treatment of hematological malignancies. Front Immunol.14:1141208.
2. Sudarsanam H, et al., 2022. Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. Front Bioeng Biotechnol.;10:886637
3. Chamucero-Millares JA, et al., 2021. Usefulness of IL-21, IL-7, and IL-15 conditioned media for expansion of antigen-specific CD8+ T cells from healthy donor-PBMCs suitable for immunotherapy. Cell Immunol.;360
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
